Humatin

Humatin is an oral, prescription‑only medication that contains paromomycin sulfate as its active ingredient. Marketed in the European Union, it is supplied in an unspecified strength and dosage form. Paromomycin belongs to the aminoglycoside class of antibiotics and provides antiprotozoal and antibacterial activity. The product is classified under ATC code A07AA02 and is intended for use under medical supervision carefully for clinically appropriate parasitic infections.

Humatin is indicated for the treatment of specific protozoal and bacterial infections that respond to oral paromomycin therapy.

- Amebiasis (infection caused by Entamoeba histolytica), typically presenting with dysentery or liver abscess. - Giardiasis, an intestinal infection caused by Giardia lamblia leading to diarrhea and malabsorption. - Cryptosporidiosis, a diarrheal disease caused by Cryptosporidium species, especially in immunocompromised patients. - Cutaneous leishmaniasis, a skin manifestation of Leishmania infection treated with systemic paromomycin. - Post‑exposure prophylaxis for travelers at risk of acquiring intestinal protozoa in endemic regions, when other options are unsuitable. - Adjunctive therapy for mixed bacterial‑protozoal gastrointestinal infections where susceptibility testing supports paromomycin use.

Adverse reactions to Humatin are generally mild but can include more serious events; monitoring is advised.

Common: - Nausea or vomiting, often transient and mild. - Abdominal cramps or pain that may accompany gastrointestinal upset. - Diarrhea or loose stools, sometimes leading to dehydration if severe. - Metallic taste in the mouth, usually resolving after treatment ends.

Serious: - Severe allergic reaction, including anaphylaxis, widespread rash, or facial swelling. - Ototoxicity presenting as hearing loss, tinnitus, or balance disturbances. - Nephrotoxicity manifested by increased serum creatinine or reduced urine output. - Clostridioides difficile‑associated colitis, characterized by profuse watery diarrhea and abdominal tenderness.

When prescribing Humatin, clinicians should evaluate patient history and monitor for conditions that may increase risk of adverse outcomes.

- Assess renal function before initiating therapy, as reduced clearance can raise systemic exposure. - Use caution in patients with pre‑existing hearing impairment due to potential ototoxicity. - Avoid use during pregnancy unless benefits outweigh risks, because safety data are limited. - Monitor for signs of allergic reaction, especially in individuals with known hypersensitivity to aminoglycosides. - Ensure adequate hydration to reduce the likelihood of nephrotoxic effects. - Consider the risk of Clostridioides difficile infection, particularly in patients with recent antibiotic exposure.

Humatin may interact with other medicines; some combinations should be avoided while others require careful monitoring.

Avoid: - Concurrent use with other nephrotoxic agents (e.g., vancomycin, amphotericin B) that can amplify kidney injury. - Co‑administration with ototoxic drugs (e.g., loop diuretics, cisplatin) increasing risk of hearing loss. - Combining with other aminoglycosides, which can lead to additive toxicity.

Use with caution: - Concurrent diuretics may affect electrolyte balance and renal clearance; monitor serum electrolytes. - Antacids containing magnesium or aluminum can reduce oral absorption of paromomycin; separate dosing times. - Use with drugs that alter gut flora (e.g., broad‑spectrum antibiotics) may increase risk of Clostridioides difficile infection.